Form 8-K - Current report:
SEC Accession No. 0001641172-25-018894
Filing Date
2025-07-14
Accepted
2025-07-14 08:01:40
Documents
14
Period of Report
2025-07-14
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39336
2 EX-99.1 ex99-1.htm EX-99.1 26310
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3612
  Complete submission text file 0001641172-25-018894.txt   246621

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE dare-20250714.xsd EX-101.SCH 3032
5 XBRL LABEL FILE dare-20250714_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE dare-20250714_pre.xml EX-101.PRE 22370
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3658
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 251120177
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)